TKIs in First-line HCC
The Evolving Role of TKIs in First-line Treatment of Advanced HCC

Released: December 14, 2021

Activity

Progress
1
Course Completed

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:

  • Atezolizumab plus bevacizumab as the current standard of care
  • Contraindications to atezolizumab plus bevacizumab
  • The current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinoma
  • Ongoing clinical trials in the first-line setting